As of the latest Form 4 filed Jul 2, 2026.
What Nurix Therapeutics Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 43 most recent filings for NRIX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | 2026-07-02 | Ring Christine Chief Legal Officer | SSale | −11.0K | $23.56 | $259K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-02 | Ring Christine, Chief Legal Officer | MExercise | +5.79K | $8.72 | $50.5K | Yes (planned) | Form 4 ↗ |
| 2026-07-02 | 2026-07-02 | Ring Christine, Chief Legal Officer | MExercise | +5.22K | $1.86 | $9.71K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-25 | Ring Christine Chief Legal Officer | SSale | −28.9K | $20.06 | $581K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-25 | Ring Christine, Chief Legal Officer | MExercise | +15.6K | $8.72 | $136K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-25 | Ring Christine, Chief Legal Officer | MExercise | +13.3K | $7.26 | $96.8K | Yes (planned) | Form 4 ↗ |
| 2026-06-25 | 2026-06-25 | Hansen Gwenn Chief Scientific Officer | SSale | −5.39K | $20.00 | $108K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-02 | Ring Christine Chief Legal Officer | SSale | −8.15K | $16.60 | $135K | Yes (planned) | Form 4 ↗ |
| 2026-06-02 | 2026-06-02 | Ring Christine, Chief Legal Officer | MExercise | +3.42K | $1.86 | $6.36K | Yes (planned) | Form 4 ↗ |
| 2026-05-04 | 2026-05-04 | Ring Christine Chief Legal Officer | SSale | −8.15K | $16.96 | $138K | Yes (planned) | Form 4 ↗ |
| 2026-05-01 | 2026-05-01 | Ring Christine Chief Legal Officer | SSale | −5.39K | $16.76 | $90.4K | Yes (planned) | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | van Houte Hans Chief Financial Officer | SSale | −2.39K | $16.65 | $39.7K | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | van Houte Hans, Chief Financial Officer | MExercise | +2.86K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | van Houte Hans, Chief Financial Officer | MExercise | +3.75K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | van Houte Hans, Chief Financial Officer | MExercise | +2.00K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | Ring Christine Chief Legal Officer | SSale | −3.21K | $16.65 | $53.5K | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | Ring Christine, Chief Legal Officer | MExercise | +2.86K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | Ring Christine, Chief Legal Officer | MExercise | +3.75K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | Ring Christine, Chief Legal Officer | MExercise | +2.00K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | Hansen Gwenn Chief Scientific Officer | SSale | −3.21K | $16.65 | $53.5K | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | Hansen Gwenn, Chief Scientific Officer | MExercise | +2.86K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | Hansen Gwenn, Chief Scientific Officer | MExercise | +3.75K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-04-30 | 2026-04-30 | Hansen Gwenn, Chief Scientific Officer | MExercise | +2.00K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-09 | 2026-02-09 | Ring Christine Chief Legal Officer | SSale | −14.3K | $16.66 | $238K | Yes (planned) | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | van Houte Hans Chief Financial Officer | SSale | −73.00 | $17.37 | $1.27K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | van Houte Hans, Chief Financial Officer | SSale | −3.59K | $16.58 | $59.5K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | van Houte Hans, Chief Financial Officer | MExercise | +2.86K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | van Houte Hans, Chief Financial Officer | MExercise | +3.75K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | van Houte Hans, Chief Financial Officer | MExercise | +2.00K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | van Houte Hans, Chief Financial Officer | MExercise | +2.89K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | Ring Christine Chief Legal Officer | SSale | −88.00 | $17.37 | $1.53K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | Ring Christine, Chief Legal Officer | SSale | −4.33K | $16.58 | $71.9K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | Ring Christine, Chief Legal Officer | MExercise | +2.86K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | Ring Christine, Chief Legal Officer | MExercise | +3.75K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | Ring Christine, Chief Legal Officer | MExercise | +2.00K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | Ring Christine, Chief Legal Officer | MExercise | +1.93K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | Hansen Gwenn Chief Scientific Officer | SSale | −98.00 | $17.37 | $1.70K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | Hansen Gwenn, Chief Scientific Officer | SSale | −4.80K | $16.58 | $79.5K | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | Hansen Gwenn, Chief Scientific Officer | MExercise | +2.86K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | Hansen Gwenn, Chief Scientific Officer | MExercise | +3.75K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | Hansen Gwenn, Chief Scientific Officer | MExercise | +2.00K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-01-30 | 2026-01-30 | Hansen Gwenn, Chief Scientific Officer | MExercise | +3.21K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-05-02 | 2024-05-02 | van Houte Hans Chief Financial Officer | SSale | −3.50K | $12.83 | $44.9K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also NRIX’s full analysis or the market-wide insider trading feed. The tabs above jump to NRIX’s other SEC data.
Source: SEC Form 4 filings for NRIX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.